

Име и презиме	<b>Невена Гајовић</b>		
Звање	Доцент		
Назив институције у којој наставник ради са пуним радним временом и од када	Факултет медицинских наука, Универзитет у Крагујевцу		2016.
Ужа научна односно уметничка област	Микробиологија и имунологија		
Академска каријера			
	Година	Институција	Област
Избор у звање	2022.	Факултет медицинских наука у Крагујевцу	Микробиологија и имунологија
Докторат	2018.	Факултет медицинских наука у Крагујевцу	Медицина
Специјализација			
Магистратура			
Диплома	2013.	Медицински факултет Универзитета у Крагујевцу	Медицина
Репрезентативне референце			
1.	Milosevic J, Jurisevic M, Grbovic V, Jovanovic I, Gajovic N, Jurisic-Skevin A. Potential Protective Role of Galectin-3 in Patients with Gonarthrosis and Diabetes Mellitus: A Cross-Sectional Study. <i>Int J Environ Res Public Health</i> . 2022;19(18):11480.		
2.	Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. <i>World J Psychiatry</i> . 2022;12(9):1183-1193.		
3.	Savic G, Stevanovic I, Mihajlovic D, Jurisevic M, Gajovic N, Jovanovic I, Ninkovic M. MMP-9/BDNF ratio predicts more severe COVID-19 outcomes. <i>Int J Med Sci</i> . 2022;19(13):1903-1911.		
4.	Jovanovic M, Gajovic N, Jurisevic M, Sekulic S, Jovic M, Jovanovic M, Lukic R, Jovanovic I, Radovanovic D, Arsenijevic N. Anti-PD-1 therapy activates tumoricidal properties of NKT cells and contributes to the overall deceleration of tumor progression in a model of murine mammary carcinoma. <i>Vojnosanit Pregl</i> . 2022;79(8):764-773.		
5.	Jovicic-Milic S, Jevtic V, Radisavljevic S, Petrovic B, Radojevic I, Rakovic I, Petrovic Dj, Stojkovic D, Jurisevic M, Gajovic N, Petrovic Andjela, Arsenijevic N, Jovanovic I, Klisuric O, Vukovic N, Kacaniovic M. Synthesis, characterization, DNA interactions and biological activity of new palladium(II) complexes with some derivatives of 2-aminothiazoles. <i>Journal of inorganic biochemistry</i> 2022;233.		
6.	Dimitrijevic Stojanovic M, Franich A, Jurisevic M, Gajovic N, Arsenijevic N, Jovanovic I, Stojanovic B, Mitrovic S, Kljun J, Rajkovic S, Zivkovic M. Platinum(II) complexes with malonic acids: Synthesis, characterization, <i>in vitro</i> and <i>in vivo</i> antitumor activity and interactions with biomolecules. <i>Journal of Inorganic Biochemistry</i> 2022; 231: 111773 DOI: 10.1016/j.jinorgbio.2022.111773		
7.	Sekulic Markovic S, Gajovic N, Jurisevic M, Jovanovic M, Popovska Jovicic B, Arsenijevic N, Mijailovic Z, Jovanovic M, Dolicanin Z, Jovanovic I. Galectin-1 as the new player in staging and prognosis of COVID-19. <i>Scientific Reports</i> 2022; DOI: 10.1038/s41598-021-04602-z		
8.	Jovic M, Arsenijevic N, Gajovic N, Jurisevic M, Jovanovic I, Jovanovic M, Zdravkovic N, Maric V, Jovanovic M. Anemia of inflammation in patients with colorectal cancer: correlation with interleukin-1, interleukin-33 and galectin-1. <i>J Med Biochem</i> . 2021;40:1-12.		
9.	Jovanovic M, Geller D, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, Supic G, Vojvodic D, Jovanovic I. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. <i>Life Sci</i> . 2022;289:120214.		
10.	Sekulic Markovic S, Jovanovic M, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, Jovanovic M, Mijailovic Z, Lukic S, Zornic N, Vukicevic V, Stojanovic J, Maric V, Jovic M and Jovanovic I. IL 33 Correlates With COVID-19 Severity, Radiographic and Clinical Finding. <i>Frontiers in Medicine</i> . 2021;8:749569.		
11.	Jovanovic-Stevic S, Cocic D, Puchta R, Bogoeski J, Jurisevic M, Gajovic N, Jakovljevic S, Arsenijevic N, Jovanovic I, Petrovic B. Assessment of biological activity of the caffeine-derived Pt (II) and Pd (II) complexes. <i>Appl Organomet Chem</i> . 2021; doi.org/10.1002/aoc.6532.		
12.	Jovic M, Gajovic N, Jurisevic M, Jovanovic M, Zdravkovic N, Arsenijevic N, Vukovic Dejanovic V, Maric V, Milev B, Jovanovic M. Colorectal carcinoma: evaluation of systemic values of interleukin-1 and interleukin-33 in patients with and without thrombocytosis. <i>Vojnosanit pregl</i> . 2021;78(6): 627-634.		
13.	Petrovic Dj, Jovicic Milic S, Djukic M, Radojevic I, Jelic R, Jurisevic M, Radic G, Gajovic N, Arsenijevic N, Jovanovic I, Markovic N, Stojkovic D, Jevtic V. Synthesis, characterization, HSA/DNA binding, cytotoxicity study, and antimicrobial activity of new palladium(II) complexes with some esters of (S,S)-propylenediamine-N,N'-di-2-(3-methyl)butanoic acid. <i>Inorganica Chimica Acta</i> . 2021;528:120601.		
14.	Jovanovic MM, Jurisevic MM, Gajovic NM, Arsenijevic NN, Jovic MV, Jovanovic IP, Zdravkovic ND, Djukic AL, Maric VJ, Jovanovic MM. Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome. <i>Tohoku J Exp Med</i> . 2021;254(3):171-182.		
15.	Kononov B, Franich A, Jovanovic M, Jurisevic M, Gajovic N, Jovanovic M, Arsenijevic N, Maric V, Jovanovic I, Zivkovic M, Rajkovic S. Synthesis, DNA/BSA-binding affinity and cytotoxicity of dinuclear platinum (II) complexes with 1,6-naphthyridine bridging ligand. <i>Appl Organomet Chem</i> 2020; DOI: 10.1002/aoc.6112.		
16.	Pavlovic M, Jurisevic M, Gajovic N, Mitrovic S, Jovanovic M, Radosavljevic G, Pantic J, Radovanovic D, Arsenijevic N, Jovanovic I. IL-32 expression associates with lymph vessel invasion in intestinal type of gastric cancer. <i>Vojnosanit Pregl</i> 2020; 77(8): 816-825.		
17.	Borovcanin M, Minic Janicijevic S, Jovanovic I, Gajovic N, Jurisevic M and Arsenijevic N. Type 17 Immune Response Facilitates Progression of Inflammation and Correlates with Cognition in Stable Schizophrenia. <i>Diagnostics</i> 2020; 10, 926; doi:10.3390/diagnostics10110926.		
18.	Bošković M, Franich A, Rajković S, Jovanović M, Jurisević M, Gajović N, Jovanović M, Arsenijević N, Jovanović I and Živković M. Potential antitumor effect of newly synthesized dinuclear 1,5-naphthyridine-bridging palladium (II) complexes. <i>ChemistrySelect</i> 2020, 5: 10549-10555.		
19.	Lukic R, Cupic M, Gajovic N, Jurisevic M, Mijailovic Z, Davidovic B, Kujundzic B, Joksimovic B, Arsenijevic N, Jovanovic I. Increased systemic sST2 in patients with end stage renal disease contributes to milder liver damage during HCV infection. <i>J Infect Dev Ctries</i> . 2020; 14(5): 519-526.		
20.	Jovanovic M, Simovic Markovic B, Gajovic N, Jurisevic M, Djukic A, Jovanovic I, Arsenijevic N, Lukic A, Zdravkovic N. Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. <i>World J Gastroenterol</i> . 2019; 25(43): 6465-6482.		
21.	Stojanovic B, Jovanovic I, Stojanovic BS, Stojanovic MD, Gajovic N, Radosavljevic G, Pantic J, Arsenijevic N, Lukic ML. Deletion of Galectin-3 attenuates acute pancreatitis in mice by affecting activation of innate inflammatory cells. <i>Eur J Immunol</i> . 2019; 49(6): 940-946.		
22.	Jovanovic M, Gajovic N, Jurisevic M, Simovic Markovic B, Maric V, Jovanovic M, Arsenijevic N, Zdravkovic N. Fecal sST2 correlates with disease severity of ulcerative colitis. <i>Vojnosanit Pregl</i> 2019; 76(11): 1153-1161.		
23.	Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Mirkovic D, Milev B, Maric V, Arsenijevic N. Fecal galectin-1 as a potential marker for colorectal cancer and disease severity. <i>Vojnosanit Pregl</i> 2019; 76(10): 1037-1044.		
24.	Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML and Jovanovic I. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. <i>Endocrine-related cancer</i> 2018; 25: 493-507.		
25.	Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A and Jovanovic I. Fecal galectin-3: A new promising biomarker for severity and progression of colorectal carcinoma. <i>Mediators of Inflammation</i> 2018; DOI: 10.1155/2018/8031328.		

26.	Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. <i>Therap Adv Gastroenterol.</i> 2018 Aug 24;11:1756284818793558. doi: 10.1177/1756284818793558.
27.	Borovcanin MM, Janicijevic SM, Jovanovic IP, Gajovic N, Arsenijevic NN, Lukic ML. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. <i>Front Psychiatry.</i> 2018 Jun 22;9:271. doi: 10.3389/fpsy.2018.00271.
28.	Jurisevic M, Jagic N, Gajovic N, Arsenijevic A, Jovanovic M, Milovanovic M, Pantic J, Jovanovic I, Sabo T, Radosavljevic G, Arsenijevic N. O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl) propanoate dihydrochloride enhances influx of effective NK and NKT cells in murine breast cancer. <i>Vojnosanit pregl.</i> 2018; doi: 10.2298/VSP180723149J.
29.	Pavlovic M, Gajovic N, Jurisevic M, Mitrovic S, Radosavljevic G, Pantic J, Arsenijevic N, Jovanovic I. Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer. <i>Gastroenterol Res Pract.</i> 2018; 2018:6578273.
30.	Pantic JM, Jovanovic IP, Radosavljevic GD, Gajovic NM, Arsenijevic NN, Conlon JM, Lukic ML. The frog skin host-defense peptide frenatin 2.1S enhances recruitment, activation and tumoricidal capacity of NK cells. <i>Peptides</i> 2017; 93:44-50.
31.	Lukic R, Gajovic N, Jovanovic I, Jurisevic M, Mijailovic Z, Maric V, Popovska Jovicic B, Arsenijevic N. Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients. <i>Dis Markers.</i> 2017;2017:6275987.
32.	Vasovic M, Gajovic N, Brajkovic D, Jovanovic M, Zdravkovic N, Kanjevac T. The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. <i>Cent Eur J Immunol.</i> 2016;41(3):302-310..
33.	Petrovic A, Markovic V, Maric V, Gajovic N. Metformin as a potential antitumor agent. <i>Ser J Exp Clin Res.</i> 2022; doi: 2478/sjecr-2022-0023.
34.	Maric V, Jovanovic M, Zdravkovic N, Jovanovic M, Gajovic N, Jurisevic M, Jovanovic M, Jovanovic I. Increased IL-33 and IL-17 in colorectal carcinoma patients with severe disease. <i>Ser J Exp Clin Res.</i> 2018; doi:10.2478/sjecr-2018-0034.
35.	Jovanovic M, Gajovic N, Lukic ML, Popovic A, Jovanovic I. Synergism of PDL/PD1 and IL33/ST2 axis in tumor immunology. <i>Ser J Exp Clin Res.</i> 2018; doi:10.2478/sjecr-2018-0033.
36.	Jurisevic M, Arsenijevic A, Pantic J, Gajovic N, Milovanovic J, Milovanovic M, Poljarevic J, Sabo T, Vojvodic D, Radosavljevic G, Arsenijevic N. The organic ester O,O'-diethyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate dihydrochloride attenuates murine breast cancer growth and metastasis. <i>Oncotarget.</i> 2018; 9(46): 28195-28212.
37.	Gajovic N, Jovanovic I, Ilic A, Jeremic N, Jakovljevic V, Arsenijevic N, Lukic M. Diabetes mellitus directs NKT cells toward type 2 and regulatory phenotype <i>Ser J Exp Clin Res</i> 2016; 17 (1): 35-41.
38.	Jurisevic M, Radosavljevic G, Arsenijevic A, Milovanovic M, Gajovic N, Djordjevic D, Milovanovic J, Stojanovic B, Ilic A, Sabo T, Kanjevac T. Platinum complexes with edda (ethylenediamine-N,N'-diacetate) ligands as potential anticancer agents. <i>Serb J Exp Clin Res.</i> DOI: 10.1515/SJECR-2016-0042
39.	Lukic R, Lukovic B, Gajović N, Prljic S, Đukic S Mechanism of intracellular chlamydiae survival <i>Ser J Exp Clin Res</i> 2016; 17 (2): 145-151.
40.	Jovanović I, Gajović N, Radosavljević G, Pantić J, Pejnović N, Arsenijević N, Lukić M. Innate lymphoid cells: roles in tumour genesis and progression <i>Ser J Exp Clin Res</i> 2015; 16 (2): 85-90.
41.	Jovanovic M, Zdravkovic N, Jovanovic I, Radosavljevic G, Gajovic N, Zdravkovic N, Maric V, Arsenijevic N. TGF-β as a marker of ulcerative colitis and disease severity. <i>Ser J Exp Clin Res</i> DOI: 10.1515/sjecr-2017-0019.

Збирни подаци научне, односно уметничке и стручне активности наставника

Укупан број цитата	Science Citation Index, Web of Science		
	Scopus		
Укупан број радова са SCI или (SSCI) листе у последњих 10 година	<b>32</b>		
Тренутно учешће на пројектима	<b>11</b>	Домаћи	<b>10</b>
		Међународни	<b>1</b>
Усавршавања			
Други релевантни подаци			